Compare Abeona Therapeutics Inc (ABEO) vs Bilibili Inc (BILI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bilibili Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Bilibili Inc trades at $18.04 (market cap $7.28B). The key difference: Bilibili Inc is far larger — about 19.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BILI | |
|---|---|---|
Market Cap | $373.32M | $7.28B |
Sector | Health | Media |
52-Week High | $7.23 | $35.92 |
52-Week Low | $4.17 | $15.96 |
Enterprise Value | $228.22M | $5.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Bilibili (BILI) trades at $17.90, up 4.43% today, with a bullish technical signal despite mixed moving average indicators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83% buy ratings. Recent news highlights a new $300 million share repurchase program and continued user growth, though revenue expansion remains moderate.
The outlook is positive given earnings beats and shareholder-friendly buybacks, but risks include competitive pressures in China's video platform market and reliance on advertising growth. Upside potential hinges on margin expansion and successful AI integration, while macroeconomic volatility poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
